Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells
Horm Metab Res DOI: 10.1055/a-1157-0166Although glucagon-like peptide-1 (GLP-1) analogue has been reported to suppress
oxidative stress in non-alcoholic fatty liver disease (NAFLD), an effective
therapeutic agent for NAFLD is currently unavailable. Therefore, in this study,
we aimed to investigate the protective effects of the GLP-1 analogue liraglutide
against lipotoxicity-induced oxidative stress in HepG2 cells and to elucidate
the underlying mechanisms. HepG2 cells were cultured for 48 hours and treated
with a free fatty acid (FFA) mixture: FFA mixture and liraglutide or FFA
mixture, liraglutide, and exendin (9–39). Lipid accumulation was
examined by oil red O staining. Oxidative stress was assessed by measuring the
levels of intracellular reactive oxygen species using
2′,7′-dichlorofluorescein diacetate and thiobarbituric
acid-reactive substances, whereas antioxidant capacity was assessed by measuring
the activity of superoxide dismutase and catalase. Expression of the nuclear
factor erythroid-2-related factor 2 (NRF2) gene and the genes encoding
antioxidant enzymes was analyzed using quantitative RT-PCR. Cellular and nuclear
NRF2 expression levels were assessed using immunofluorescence cell staining and
western blotting. Liraglutide treatment reduced high fat-induced lipid formation
and the levels ...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Zhu, Chong-gui Luo, Ying Wang, Hao Li, Jun-Yi Yang, Jie Liu, Ya-xin Qu, Hui-qi Wang, Bao-li Zhu, Mei Tags: Endocrine Research Source Type: research
More News: Alcoholism | Antidoxidants | Endocrinology | Fatty Liver Disease (FLD) | Genetics | High Fat | Hormones | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Study | Translocation | Urology & Nephrology | Victoza